<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Warfarin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00682</strong>&#160; (APRD00341)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00682/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00682/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00682.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00682.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00682.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00682.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00682.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00682">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Coumafene</td><td>French</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zoocoumarin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Warfarin sodium</strong>
          <div class="cas">129-06-6</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000278/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000278/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: KYITYFHKDODNCQ-UHFFFAOYNA-M</li>
              <li>Monoisotopic Mass: 330.086803643</li>
              <li>Average Mass: 330.3098</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000278">DBSALT000278</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Coumadin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Jantoven</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lawarin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Marevan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Waran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Warfant</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticoagulants">Anticoagulants</a></li>
<li><a href="/mesh/rodenticides">Rodenticides</a></li></ul></td></tr><tr><th>CAS number</th><td>81-81-2</td></tr><tr><th>Weight</th><td>Average: 308.3279<br>Monoisotopic: 308.104859</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>16</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>PJVWKTKQMONHTI-UHFFFAOYNA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00682.gif?1265922773">show</a>(8.72 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Coumarins and Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Coumarins and Derivatives</td></tr><tr><th>Alternative parents</th><td>Benzopyrans; Pyranones and Derivatives; Benzene and Substituted Derivatives; Ketones; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>pyranone; benzene; pyran; ketone; enolate; polyamine; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.</td></tr><tr><th>Pharmacodynamics</th><td>Warfarin, a coumarin anticoagulant, is a racemic mixture of two active isomers. It is used in the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).</td></tr><tr><th>Mechanism of action</th><td>Warfarin inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed following oral administration with considerable interindividual variations. Also absorbed percutaneously. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.14 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>99% bound primarily to albumin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized stereo- and regio-selectively by hepatic microsomal enzymes. S-warfarin is predominantly metabolized by cytochrome P450 (CYP) 2C9 to yield the 6- and 7-hydroxylated metabolites. R-warfarin is metabolized by CYP1A1, 1A2, and 3A4 to yield 6-, 8-, and 10-hydroxylated metabolites. Hydroxylated metabolites may be further conjugated prior to excretion into bile and urine. UGT1A1 appears to be responsible for producing the 6-O-glucuronide of warfarin, with a possibly contribution from UGT1A10. Five UGT1As may be involved in the formation of 7-O-glucuronide warfarin. S-warfarin has higher potency than R-warfarin and genetic polymorphisms in CYP2C9 may dramatically decrease clearance of and increase toxicity of the medication. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00043">S-6-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/43">Details</a></td></tr><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00044">S-4'-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/44">Details</a></td></tr><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li></ul></td><td><a href="/metabolites/DBMET00045">R-4'-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/45">Details</a></td></tr><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li></ul></td><td><a href="/metabolites/DBMET00046">R-6-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/46">Details</a></td></tr><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00047">R-10-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/47">Details</a></td></tr><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00048">R-8-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/48">Details</a></td></tr><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET00049">R-7-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/49">Details</a></td></tr><tr><td>Warfarin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET01042">S-7-Hydroxywarfarin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1046">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>The elimination of warfarin is almost entirely by metabolism. Very little warfarin is excreted unchanged in urine. The metabolites are principally excreted into the urine; and to a lesser extent into the bile.</td></tr><tr><th>Half life</th><td>R-warfarin t<sub>1/2</sub>=37-89 hours; S-warfarin t<sub>1/2</sub>=21-43 hours. </td></tr><tr><th>Clearance</th><td><ul>
	<li>0.065 +/- 0.025 mL/min/kg [CYP2C9 Genotype <strong>1/</strong>1]</li>
	<li>0.041 +/- 0.021  [CYP2C9 Genotype <strong>1/</strong>2 or <strong>1/</strong>3]</li>
	<li>0.020 +/- 0.011  [CYP2C9 Genotype <strong>2/</strong>2, <strong>2/</strong>3, or <strong>3/</strong>3]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=374 (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Warfarin Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2C9<br>Gene symbol: CYP2C9<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P11712" target="_blank">P11712 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1799853" target="_blank">rs1799853 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C9*2</td><td>T Allele</td><td>Poor drug metabolizer, lower dose requirements</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15608560" target="_blank" title="King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22.">15608560 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9109</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9124</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5502</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8863</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.678</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.5658</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6007</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.714</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.7657</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9286</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9161</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8785</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6844
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9352
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7474
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          4.1700 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8768
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9615
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmaceutical research assoc inc</li>
<li>Bristol myers squibb pharma co</li>
<li>Usl pharma inc</li>
<li>Abbott laboratories pharmaceutical products div</li>
<li>Barr laboratories inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva inc</li>
<li>Sandoz inc</li>
<li>Taro pharmaceuticals inc</li>
<li>Watson laboratories inc</li>
<li>Zydus pharmaceuticals usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apothecon.nl">Apothecon</a></li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bpipack.com">Blenheim Pharmacal</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.coastalfamilyhealth.org">Coastal Family Health Center Inc.</a></li>
<li>Dept Health Central Pharmacy</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Genpharm LP</li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.ipcalabs.com">Ipca Laboratories Ltd.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.upsher-smith.com">Upsher Smith Laboratories</a></li>
<li>USL Pharma Inc.</li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>1 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>2 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>2.5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>3 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>4 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>6 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>7.5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00316">Acetaminophen</a></td><td>Acetaminophen increases the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if acetaminophen is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>The antiplatelet effects of acetylsalicylic acid may increase the bleed risk associated with warfarin.</td></tr><tr><td><a href="/drugs/DB00437">Allopurinol</a></td><td>Allopurinol may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin times and therapeutic effects of warfarin if allopurinol is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00357">Aminoglutethimide</a></td><td>Aminoglutethimide may decrease the anticoagulant effect of warfarin by increasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if aminoglutethimide is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00233">Aminosalicylic Acid</a></td><td>The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin. </td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>Amobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if amobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the anticoagulant effect of warfarin by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB06237">Avanafil</a></td><td>Co-administration with avanafil resulted in an approximate 1.6% increase in AUC(0-inf) and 5.2% decrease in Cmax of S-warfarin.
</td></tr><tr><td><a href="/drugs/DB00993">Azathioprine</a></td><td>Azathioprine may decrease the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00207">Azithromycin</a></td><td>Azithromycin may increase the anticoagulant effect of warfarin by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>Bezafibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if bezafibrate is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01101">Capecitabine</a></td><td>Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01330">Cefotetan</a></td><td>The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01331">Cefoxitin</a></td><td>The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01212">Ceftriaxone</a></td><td>The cephalosporin, ceftriaxone, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00482">Celecoxib</a></td><td>Celecoxib may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of warfarin by decreasing its absorption.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the serum concentration of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if cimetidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00537">Ciprofloxacin</a></td><td>The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Cisapride may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>The SSRI, citalopram, increases the effect of anticoagulant, warfarin.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00636">Clofibrate</a></td><td>The fibrate increases the anticoagulant effect</td></tr><tr><td><a href="/drugs/DB00758">Clopidogrel</a></td><td>Increased bleed risk may occur as a result of additive anticoagulant effects. Increase monitoring for signs and symptoms of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00375">Colestipol</a></td><td>The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of warfarin by decreasing its absorption.</td></tr><tr><td><a href="/drugs/DB00531">Cyclophosphamide</a></td><td>The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01406">Danazol</a></td><td>Danazol may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if danazol is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if delavirdine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00304">Desogestrel</a></td><td>Desogestrol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if desogestrol is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00647">Dextropropoxyphene</a></td><td>Propoxyphene may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00509">Dextrothyroxine</a></td><td>The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00586">Diclofenac</a></td><td>The antiplatelet effects of oral diclofenac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00485">Dicloxacillin</a></td><td>Dicloxacillin may decrease the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00861">Diflunisal</a></td><td>The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00822">Disulfiram</a></td><td>Disulfiram may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Dronedarone is a moderate inhibitor of CYP3A4 which is responsible for warfarin metabolism. Increases serum concentration of S-isomer warfarin by 1.2 fold </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00055">Drotrecogin alfa</a></td><td>Increased risk of bleeding.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00189">Ethchlorvynol</a></td><td>Ethchlorvynol may decrease the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Ethinyl estradiol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethinyl estradiol is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00823">Ethynodiol</a></td><td>Ethynodiol diacetate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethynodiol diacetate is initiated, discontinued or dose </td></tr><tr><td><a href="/drugs/DB00749">Etodolac</a></td><td>The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00294">Etonogestrel</a></td><td>Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01628">Etoricoxib</a></td><td>Etoricoxib may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00973">Ezetimibe</a></td><td>If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.</td></tr><tr><td><a href="/drugs/DB06223">F</a></td><td>decreases the effect of cortisone by metabolism alteration. </td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00573">Fenoprofen</a></td><td>The antiplatelet effects of fenoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00322">Floxuridine</a></td><td>Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if floxuridine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00544">Fluorouracil</a></td><td>Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>The SSRI, fluoxetine, increases the effect of anticoagulant, warfarin.</td></tr><tr><td><a href="/drugs/DB01185">Fluoxymesterone</a></td><td>Fluoxymesterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if fluoxymesterone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00712">Flurbiprofen</a></td><td>Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01095">Fluvastatin</a></td><td>Fluvastatin may increase the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if fluvastatin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Increased hydantoin levels and risk of bleeding</td></tr><tr><td><a href="/drugs/DB06705">Gadofosveset trisodium</a></td><td>In a clinical trial of 10 patients receiving a stable dose of warfarin, a single dose of ABLAVAR (0.05 mmol/kg) did not alter 
the anticoagulant activity of warfarin as measured by the International Normalized Ratio (INR).</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>Gefitinib may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00441">Gemcitabine</a></td><td>Gemcitabine may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if gemfibrozil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01404">Ginseng</a></td><td>Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01437">Glutethimide</a></td><td>Glutethimide may decrease the serum concentration of warfarin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if glutethimide is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>Griseofulvin may decrease the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB04865">Homoharringtonine</a></td><td>Avoid combination with warfarin and other anticoagulants due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. </td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00465">Ketorolac</a></td><td>The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01097">Leflunomide</a></td><td>Leflunomide may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00848">Levamisole</a></td><td>Levamisole may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Levonorgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if levonorgestrel is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00451">Levothyroxine</a></td><td>Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00279">Liothyronine</a></td><td>Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01583">Liotrix</a></td><td>Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08827">Lomitapide</a></td><td>Warfarin plasma concentrations may increase by lomitapide by 30%..
INR levels may increase by 22%. Regular INR monitoring is required. </td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Lovastatin may increase the anticoagulant effect warfarin.  Monitor for changes in the therapeutic and adverse effects of warfarin if lovastatin is initiated, discontinued or dose changed .</td></tr><tr><td><a href="/drugs/DB01283">Lumiracoxib</a></td><td>Lumiracoxib may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00939">Meclofenamic acid</a></td><td>The antiplatelet effects of meclofenamic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00784">Mefenamic acid</a></td><td>Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00358">Mefloquine</a></td><td>Mefloquine may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00814">Meloxicam</a></td><td>The antiplatelet effects of meloxicam may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01033">Mercaptopurine</a></td><td>Mercaptopurine may decrease the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00763">Methimazole</a></td><td>Methimazole may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if methimazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if miconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>The tetracycline, minocycline, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB08893">Mirabegron</a></td><td>Mirabegron increased Cmax and AUC of S- and R-warfarin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00648">Mitotane</a></td><td>Mitotane may decrease the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00218">Moxifloxacin</a></td><td>The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00461">Nabumetone</a></td><td>The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00607">Nafcillin</a></td><td>Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00779">Nalidixic Acid</a></td><td>The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB08804">Nandrolone decanoate</a></td><td>Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00984">Nandrolone phenpropionate</a></td><td>Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00788">Naproxen</a></td><td>The antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01059">Norfloxacin</a></td><td>The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00957">Norgestimate</a></td><td>Norgestimate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestimate is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01165">Ofloxacin</a></td><td>The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01083">Orlistat</a></td><td>Orlistat may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00621">Oxandrolone</a></td><td>Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00991">Oxaprozin</a></td><td>The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB06412">oxymetholone</a></td><td>Oxymetholone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxymetholone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB03585">Oxyphenbutazone</a></td><td>The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>The SSRI, paroxetine, increases the effect of the anticoagulant, warfarin.</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00806">Pentoxifylline</a></td><td>Pentoxifylline may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00812">Phenylbutazone</a></td><td>The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01022">Phylloquinone</a></td><td>Phytonadione (vitamin K) may antagonize the anticoagulant effects of warfarin. Monitor for changes in prothrombin time if phytonadione intake (either via supplements or vitamin K-rich foods) is increased or decreased. </td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06209">Prasugrel</a></td><td>Coadministration with warfarin may increase the risk of bleeding. </td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The corticosteroid, prednisolone, alters the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The corticosteroid, prednisone, alters the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The barbiturate, primidone, decreases the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Propafenone may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00550">Propylthiouracil</a></td><td>Propylthiouracil may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if propylthiouracil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Quinidine may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9.</td></tr><tr><td><a href="/drugs/DB00863">Ranitidine</a></td><td>Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence)</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00118">S-Adenosylmethionine</a></td><td>Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01398">Salicylate-sodium</a></td><td>The antiplatelet effects of sodium salicylate may increase the bleed risk associated with warfarin.</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>Secobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if secobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB06268">Sitaxentan</a></td><td>Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Warfarin doses should be decreased by 80% upon initiated of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of warfarin if sitaxentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Sucralfate may reduce the absorption of warfarin. Warfarin should be administered at least 2 hours before or 6 hours after sucralfate administration. Monitor for changes in prothrombin time if sucralfate is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00359">Sulfadiazine</a></td><td>Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01015">Sulfamethoxazole</a></td><td>Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01138">Sulfinpyrazone</a></td><td>Sulfinpyrazone may increase the anticoagulant effect of warfarin by decreasing its metabolism and protein binding. </td></tr><tr><td><a href="/drugs/DB00263">Sulfisoxazole</a></td><td>Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00469">Tenoxicam</a></td><td>The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00894">Testolactone</a></td><td>Testolactone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testolactone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00624">Testosterone</a></td><td>Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01420">Testosterone Propionate</a></td><td>The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Tetracycline may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Increased bleeding risk. Monitor INR.</td></tr><tr><td><a href="/drugs/DB00560">Tigecycline</a></td><td>Tigecycline may increase the serum concentration of warfarin.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>The antiplatelet effects of tolmetin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB05275">transdermal testosterone gel</a></td><td>The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB08814">Triflusal</a></td><td>The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of warfarin to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. </td></tr><tr><td><a href="/drugs/DB01157">Trimetrexate</a></td><td>The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use.</td></tr><tr><td><a href="/drugs/DB01401">Trisalicylate-choline</a></td><td>The antiplatelet effects of trisalicylate-choline may increase the bleed risk associated with warfarin.</td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Vemurafenib increases the AUC of S-warfarin (CYP2C9 substrate). Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>Increased risk of bleeding with concomitant use of warfarin and vilazodone.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid drastic changes in dietary habit.</li>
<li>Avoid St. John's Wort.</li>
<li>Consult your doctor before ingesting large amounts of dietary Vitamin K (e.g. from green leafy vegetables).</li>
<li>Limit garlic, ginger, gingko, and horse chestnut.</li></ul></td></tr></tbody></table>